← Back to Patent Explorer
US4762701A Expired / Lapsed US ⏱️ 0.0 years remaining

In vivo cellular tracking

Assignee: SKB AND ZYNAXIS CELL SCIENCE Inc A CORP OF PENNSYLVANIA
•
Filing: 1986-10-31
•
Granted: 1988-08-09
•
Expires: 2006-10-31
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Methods of tracking cells in vivo and for determining in vivo cell lifetimes. Cells are labelled with cyanine dyes and detection is by measuring fluorescence, absorbance, or by detecting nuclear magnetic resonance probes included in the cyanine dyes. Using the invented methods, for example, red blood cell and platelet lifetimes are determined. Also, cells are tracked to determine sites of primary or metastatic tumors, or sites of occult infection. Further, rates at which cells pass through vessels is used to determine blood vessel patency and platelet aggregation.

Inventors

  • 👤 Paul K. Horan
  • 👤 Sue E. Slezak

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-28 13:01
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/001; A61K49/0013; A61K49/0017; A61K49/0019; A61K49/0021; A61K49/0032; A61K49/005; A61K49/0058; A61K49/0063; A61K49/0069; A61K49/0097

Claims Analysis

Total Claims: 43
Claim 1
Independent Claim 24 words
A method for tracking cells in vivo in a subject that comprises determining the location of cyanine dye-labelled cells previously administered to the subject.
Claim 2
Independent Claim 24 words
A method for tracking cells in vivo in a subject that comprises determining the location of cyanine dye-labelled cells previously administered to the subject.
Claim 3
Dependent Claim 15 words
A method of claim 1 wherein the cyanine dye has a nuclear magnetic resonance probe.
Claim 4
Dependent Claim 22 words
A method of claim 1 wherein the cyanine dye-labelled cells are tumor cell-seeking so that primary or metastatic tumor cells are detected.
Claim 5
Dependent Claim 15 words
A method of claim 3 wherein the cyanine dye-labelled cells are lymphocytes or natural-killer cells.
Claim 6
Dependent Claim 19 words
A method of claim 4 wherein the lymphocytes or natural-killer cells are activated prior to administration to the subject.
Claim 7
Dependent Claim 14 words
A method of claim 3 wherein the tumor cell-seeking cyanine dye-labelled cells are monocytes.
Claim 8
Dependent Claim 28 words
A method of claim 3 wherein the tumor cell-seeking cells are monocytes having tumor specific monoclonal antibodies bound to the monocytes so that tumor cell recognition is maintained.
Claim 9
Dependent Claim 14 words
A method of claim 3 wherein the tumor cell-seeking cyanine dye-labelled cells are platelets.
Claim 10
Dependent Claim 14 words
A method of claim 3 wherein the tumor cell-seeking cyanine dye-labelled cells are neutrophils.
Claim 11
Dependent Claim 17 words
A method of claim 1 wherein the cyanine dye is DISC 14 (5) or DIOC 14 (3).
Claim 12
Dependent Claim 15 words
A method of claim 10 wherein the cyanine dye is tagged with a gamma emitter.
Claim 13
Dependent Claim 17 words
A method of claim 10 wherein the cyanine dye is tagged with a nuclear magnetic resonance probe.
Claim 14
Dependent Claim 25 words
A method of claim 1 wherein the cyanine dye-labelled cells specifically interact with an organism infecting the subject so that the infection site is determined.
Claim 15
Dependent Claim 13 words
A method of claim 13 wherein the organism is a bacterium or fungus.
Claim 16
Dependent Claim 12 words
A method of claim 14 wherein the cyanine dye-labelled cells are neutrophils.
Claim 17
Dependent Claim 14 words
A method of claim 1 wherein the cyanine dye-labelled cells are red blood cells.
Claim 18
Dependent Claim 26 words
A method of claim 16 wherein the subject's retina is examined for presence of cyanine dye-labelled red blood cells to detect retinopathv or blood vessel degeneration.
Claim 19
Dependent Claim 22 words
A method of claim 16 wherein the rate at which the cyanine dye-labelled red blood cells flow through blood vessels is measured.
Claim 20
Dependent Claim 19 words
A method of claim 16 wherein the excitation wavelength of the cyanine dye is outside the human visable spectrum.
Claim 21
Dependent Claim 12 words
A method of claim 1 wherein the cyanine dye-labelled cells are platelets.
Claim 22
Dependent Claim 17 words
A method of claim 20 wherein aggregates of cvanine dye-labelled platelets are detected in retinal blood vessels.
Claim 23
Dependent Claim 16 words
A method of claim 1 wherein the cyanine dye-labelled cells are monocytes, neutrophils, lymphocytes, or platelets.
Claim 24
Dependent Claim 15 words
A method of claim 22 wherein the cyanine dye is tagged with a gamma emitter.
Claim 25
Dependent Claim 18 words
A method of claim 23 wherein the cyanine dye-labelled neutrophils are used to detect the location of infection.
Claim 26
Dependent Claim 18 words
A method of claim 23 wherein cyanine dye-labelled cells are used with imaging methods to determine arterial constriction.
Claim 27
Dependent Claim 17 words
A method of claim 23 wherein the cyanine dye-labelled cells are used in the staging of arthritis.
Claim 28
Dependent Claim 18 words
A method of claim 23 wherein the cyanine dye-labelled cells are use to monitor transplant or organ rejection.
Claim 29
Independent Claim 29 words
A method for determining in vivo cell lifetime in a subject that comprises measuring the rate at which cyanine dye-labelled cells administered to the subject disappear from said subject.
Claim 30
Independent Claim 29 words
A method for determining in vivo cell lifetime in a subject that comprises measuring the rate at which cyanine dye-labelled cells administered to the subject disappear from said subject.
Claim 31
Dependent Claim 17 words
A method of claim 28 wherein the cyanine dye-labelled cells are used in the staging of arthritis.
Claim 32
Dependent Claim 14 words
A method of claim 28 wherein the cyanine dye-labelled cells are red blood cells.
Claim 33
Dependent Claim 34 words
A method of claim 30 wherein the rate of disappearance of the cyanine dye-labelled red blood cells is compared to hematocrit changes to distinguish between bleeding and immunologic reaction to the red blood cells.
Claim 34
Dependent Claim 27 words
A method of claim 30 wherein total blood volume is determined by injecting a fixed number of completely labelled cells and measuring the dilution factor after equilibration.
Claim 35
Dependent Claim 19 words
A method of claim 30 wherein the cyanine dye-labelled red blood cells are prepared by labelling the subject's cells.
Claim 36
Dependent Claim 23 words
A method of claim 30 wherein the cyanine dye-labelled red blood cells are prepared by labelling random donor type O red blood cells.
Claim 37
Dependent Claim 12 words
A method of claim 28 wherein the cyanine dye-labelled cells are platelets.
Claim 38
Dependent Claim 35 words
A method of claim 35 wherein the rate of disappearance of the cyanine dye-labelled platelets is compared to total platelet counts to distinguish between bleeding or decreased platelet production and immunologic reaction to the platelets.
Claim 39
Dependent Claim 19 words
A method of claim 35 where the lifetime of cyanine dye-labelled platelets is determined as a measure of atherosclerosis.
Claim 40
Dependent Claim 17 words
A method of claim 28 wherein the cyanine dye is DiSC 14 (5) or DiOC 14 (3).
Claim 41
Dependent Claim 15 words
A method of claim 38 wherein cyanine dye-labelled platelets are measured intraocularly to detect microemboli.
Claim 42
Independent Claim 39 words
A method for tracking cells in vivo in a subject that comprises: obtaining cells to be cyanine dye-labelled, labelling the cells with a cyanine dye, administering the cyanine dye-labelled cells to the subject, and detecting the cyanine dye-labelled cells.
Claim 43
Independent Claim 39 words
A method for tracking cells in vivo in a subject that comprises: obtaining cells to be cyanine dye-labelled, labelling the cells with a cyanine dye, administering the cyanine dye-labelled cells to the subject, and detecting the cyanine dye-labelled cells.

References Cited (Backward Citations)

US3673410A Cited
US4343782A Cited
US4424201A Cited
US4478815A Cited
US4401647A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1991-08-09 1992-02-08 1992-08-09 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1995-08-09 1996-02-08 1996-08-09 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1999-08-09 2000-02-08 2000-08-09 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag